FUS P525L

FUS is an RNA-binding protein essential for proper gene expression, RNA processing, and DNA damage repair in neurons. Mutations in FUS cause familial forms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), with the R521C variant representing one of several disease-causing changes near the protein's C-terminal nuclear localization signal [1][2]. The structural prediction for FUS R521C yielded an average confidence score (pLDDT) of only 50.4, substantially below the 70-point threshold considered reliable for structural interpretation. This low confidence suggests the mutation may significantly destabilize the protein's normal folding pattern or promote conformational flexibility that computational methods cannot accurately capture. Experimental studies reveal that R521C operates primarily through gain-of-function mechanisms rather than simple loss of protein activity [1][2]. The mutant protein forms abnormally stable complexes with normal (wild-type) FUS, interfering with critical protein-protein interactions and extending the mutant protein's half-life to approximately 21 hours compared to 12 hours for normal FUS [1]. This increased stability appears paradoxical given the low computational confidence score, but likely reflects the formation of aberrant protein assemblies rather than a well-folded stable structure. The mutation disrupts FUS interactions with histone deacetylase 1 (HDAC1), impairing DNA damage response pathways and leading to elevated DNA damage markers in over 50% of neurons in experimental models compared to 20% in controls [1][2]. The R521C mutation profoundly affects neuronal structure and function through multiple mechanisms [1][2]. Neurons expressing mutant FUS show reduced dendritic branching (2.8 primary branches versus 3.7-3.9 in controls), smaller axonal growth cones (74% of normal size), decreased spine density, and shorter postsynaptic densities [1]. RNA sequencing studies reveal widespread transcription and splicing defects in genes controlling dendritic growth and synaptic function, with particularly severe effects on brain-derived neurotrophic factor (BDNF) processing and transport [1]. The mutant protein also sequesters survival motor neuron (SMN) protein, reducing levels of critical small nuclear RNAs needed for proper RNA splicing [2]. In mouse models, these cellular defects translate to approximately 55% motor neuron loss by end-stage disease, partial or complete neuromuscular junction denervation, and progressive motor dysfunction [2]. The low structural confidence observed in this prediction likely reflects genuine biophysical properties of the mutant protein rather than computational limitations. FUS contains intrinsically disordered regions that lack fixed three-dimensional structure under normal conditions, and the R521C mutation may enhance this disorder or promote formation of multiple alternative conformations that AlphaFold2 cannot resolve into a single high-confidence model. This structural ambiguity at the computational level mirrors the protein's pathological behavior in cells, where it forms abnormal assemblies and disrupts normal cellular organization. While the low-confidence prediction precludes detailed structural analysis of specific molecular interactions, it provides indirect evidence that R521C fundamentally alters FUS protein behavior in ways consistent with its severe disease-causing effects observed experimentally.